Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants

doi:doi:10.1038/sj.bmt.1705031

Bone Marrow Transplantation (2005) 36, 233–235. doi:10.1038/sj.bmt.1705031; published online 23 May 2005

Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants

S Damodar¹, B George¹, J Mammen², V Mathews¹, A Srivastava¹ and M Chandy¹

¹Department of Hematology, Christian Medical College, Vellore, India
²Department of Clinical Pathology and Blood Banking, Christian Medical College, Vellore, India

Correspondence: Professor M Chandy, Department of Hematology, Christian Medical College, Vellore 632004, Tamilnadu, India. E-mail: haemat@cmcvellore.ac.in

Received 12 July 2004; Accepted 30 March 2005; Published online 23 May 2005.

Top

Abstract

Major ABO incompatibility in stem cell transplant recipients has been associated with pure red cell aplasia (PRCA). Reduction of incompatible isohaemagglutinin titres pre-transplant by various methods has been thought to reduce the incidence of PRCA. Our data suggest that pre-transplant reduction of incompatible isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of PRCA. We also failed to find any relationship between pre-transplant ABO isohaemagglutinin titre and the risk of developing PRCA.